PL2872896T3 - Status zakażenia gruźlicą u osobnika - Google Patents

Status zakażenia gruźlicą u osobnika

Info

Publication number
PL2872896T3
PL2872896T3 PL13737831T PL13737831T PL2872896T3 PL 2872896 T3 PL2872896 T3 PL 2872896T3 PL 13737831 T PL13737831 T PL 13737831T PL 13737831 T PL13737831 T PL 13737831T PL 2872896 T3 PL2872896 T3 PL 2872896T3
Authority
PL
Poland
Prior art keywords
status
individual
tuberculosis infection
tuberculosis
infection
Prior art date
Application number
PL13737831T
Other languages
English (en)
Inventor
Mahavir Singh
Mario M. Delios
Chiara Della Bella
Original Assignee
Lionex Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lionex Gmbh filed Critical Lionex Gmbh
Publication of PL2872896T3 publication Critical patent/PL2872896T3/pl

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/195—Assays involving biological materials from specific organisms or of a specific nature from bacteria
    • G01N2333/35—Assays involving biological materials from specific organisms or of a specific nature from bacteria from Mycobacteriaceae (F)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/54—Interleukins [IL]
    • G01N2333/55—IL-2
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/902—Oxidoreductases (1.)
    • G01N2333/906—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.7)
    • G01N2333/90605—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.7) acting on the CH-NH2 group of donors (1.4)
    • G01N2333/90611—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.7) acting on the CH-NH2 group of donors (1.4) with NAD or NADP as acceptor (1.4.1) in general
    • G01N2333/90616—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.7) acting on the CH-NH2 group of donors (1.4) with NAD or NADP as acceptor (1.4.1) in general with a definite EC number (1.4.1.-)

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
PL13737831T 2012-07-16 2013-07-16 Status zakażenia gruźlicą u osobnika PL2872896T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP12176506.9A EP2687848A1 (en) 2012-07-16 2012-07-16 Status of tuberculosis infection in an individual
PCT/EP2013/065002 WO2014012928A1 (en) 2012-07-16 2013-07-16 Status of tuberculosis infection in an individual
EP13737831.1A EP2872896B1 (en) 2012-07-16 2013-07-16 Status of tuberculosis infection in an individual

Publications (1)

Publication Number Publication Date
PL2872896T3 true PL2872896T3 (pl) 2018-08-31

Family

ID=48795573

Family Applications (1)

Application Number Title Priority Date Filing Date
PL13737831T PL2872896T3 (pl) 2012-07-16 2013-07-16 Status zakażenia gruźlicą u osobnika

Country Status (13)

Country Link
EP (2) EP2687848A1 (pl)
CN (1) CN104541169B (pl)
AU (1) AU2013292040B2 (pl)
CA (1) CA2878497C (pl)
DK (1) DK2872896T3 (pl)
EA (1) EA030721B1 (pl)
ES (1) ES2666073T3 (pl)
IN (1) IN2015MN00140A (pl)
NO (1) NO2872896T3 (pl)
PL (1) PL2872896T3 (pl)
PT (1) PT2872896T (pl)
WO (1) WO2014012928A1 (pl)
ZA (1) ZA201500254B (pl)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3171170A1 (en) * 2015-11-17 2017-05-24 Lionex GmbH Device for use in elispot
KR20180104038A (ko) * 2016-01-20 2018-09-19 시아먼 유니버시티 활동성 결핵의 진단을 위한 방법 및 키트
CN106501530A (zh) * 2017-01-05 2017-03-15 复旦大学附属华山医院 一种诊断结核杆菌感染的生物标志物及其相关试剂盒
RU2726789C1 (ru) * 2020-01-17 2020-07-15 Федеральное государственное бюджетное учреждение "Национальный медицинский исследовательский центр фтизиопульмонологии и инфекционных заболеваний" Министерства здравоохранения Российской Федерации (ФГБУ "НМИЦ ФПИ" Минздрава России) Способ иммунологического определения активности туберкулезной инфекции у детей и подростков с латентной инфекцией
CN115598353A (zh) * 2022-10-24 2023-01-13 首都医科大学附属北京胸科医院（Cn） 细胞因子作为标记物在制备肺外结核诊断或治疗预后产品中的应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6641814B1 (en) * 1997-04-02 2003-11-04 Statens Serum Institut Nucleic acids fragments and polypeptide fragments derived from M. tuberculosis
AU744325B2 (en) 1997-01-29 2002-02-21 Lionex Gmbh Test kit for tuberculosis diagnosis or the like
ES2534428T3 (es) * 2005-07-26 2015-04-22 Rutgers, The State University Of New Jersey Perfiles de anticuerpos específicos de un estado tuberculoso
DE102007052518A1 (de) * 2007-10-29 2009-04-30 Autoimmun Diagnostika Gmbh Verfahren zur in vitro-Diagnose und/oder in vitro- Therapieverfolgung von Infektionen
CN102033129A (zh) * 2009-09-29 2011-04-27 上海英伯肯医学生物技术有限公司 用抗原刺激的细胞免疫反应来检测病原微生物的方法及测试笔

Also Published As

Publication number Publication date
CN104541169A (zh) 2015-04-22
EA201590220A1 (ru) 2015-06-30
NO2872896T3 (pl) 2018-05-26
AU2013292040A1 (en) 2015-02-05
ES2666073T3 (es) 2018-04-30
EA030721B1 (ru) 2018-09-28
CA2878497A1 (en) 2014-01-23
PT2872896T (pt) 2018-04-02
EP2872896B1 (en) 2017-12-27
EP2687848A1 (en) 2014-01-22
CN104541169B (zh) 2017-09-15
EP2872896A1 (en) 2015-05-20
DK2872896T3 (en) 2018-04-09
CA2878497C (en) 2021-06-08
IN2015MN00140A (pl) 2015-10-16
ZA201500254B (en) 2016-06-29
WO2014012928A1 (en) 2014-01-23
AU2013292040B2 (en) 2018-07-12

Similar Documents

Publication Publication Date Title
IL269045B (en) Aptamers and their uses
HK1202545A1 (en) New diazaspirocycloalkane and azaspirocycloalkane
IL233051A0 (en) Anti-phf-tau antibodies and uses thereof
IL234628A0 (en) Imidazolyl-pyrimidines are converted into amino-indolyl and their use as drugs
HK1200822A1 (en) Substituted dipyridylamines and uses thereof
HK1210949A1 (en) Combinations and uses thereof
IL229844B (en) Anti-psgl-1 antibodies and their use
HK1191034A1 (en) N-carboxyalkyl-auristatins and use thereof n-
GB201513279D0 (en) Micro-evolution of microbes
ZA201501124B (en) Trans-clomiphene formulations and uses thereof
GB201216649D0 (en) Agents and methods
EP2688588A4 (en) FAST AND LONG-TERM IMMUNOLOGICAL THERAPEUTIC
ZA201500254B (en) Status of tuberculosis infection in an individual
EP2716359A4 (en) COMPLEX AND USES THEREOF
EP2693879A4 (en) MIGRASTATINES AND THEIR USES
HK1198587A1 (en) Isothiazolopyridine-2-carboxamides and their use as pharmaceuticals -2-
ZA201408128B (en) Etract of greyia radlkoferi and use thereof
PL2895176T3 (pl) Związek pośredni Rywaroksabanu i jego wytwarzanie
EP2787810A4 (en) INORGANIC PYROPHOSPHATE AND USES THEREOF
HK1209067A1 (en) Microneedle arrangement and adapter
GB201211961D0 (en) Methods and groups
GB201208845D0 (en) Methods and groups
GB201222541D0 (en) Kiddibidet and pottibidet
IL218974A0 (en) Conaction bitwen coutch and playels
GB201202021D0 (en) Co-sleeper and breastfeeder